PharmaDrug Inc (CSE:BUZZ) (OTCPINK:LMLLF) CEO Daniel Cohen tells Proactive the group has reported promising initial results from its study looking at using cepharanthine to treat cancer.
Cohen says 35 of the 60 cell lines showed a “marked response” to cepharanthine from cancer cell lines compared to the current standard of care. The group will await results from the final 25 within the next two weeks.